Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

safety and efficacy of CDP-1050, the availability of CDP-1050 worldwide to treat ill heart failure patients, ATPace's expected entry into a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia and the anticipated results of the trial, and CDP-1050's expected commencement of a Phase 2 clinical trial for the treatment of heart failure. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Such risks include the risk that the clinical trial for approval of ATPace and the Phase 2 clinical trial for our CDP-1050 may not be successful, that our preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease may not be successful, and that our technology may not lead to expected results including the development or the successful commercialization of technologies relating to the use of ATP or nitric oxide. Additional uncertainties and risks are described in Cordex's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to Cordex on the date hereof. Cordex undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.


'/>"/>
SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... As part of its 2015 growth plan and as a ... technical service business units, Whitehouse Laboratories is pleased to announce that it has begun ... Container Center of Excellence and will be strictly dedicated to basic USP 51, USP 61, ...
(Date:7/29/2015)... , July 30, 2015 ... santé, publie ses résultats pour le premier semestre ... commente les résultats. Visionner l,interview vidéo ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de l,interview ... - Moteurs de croissance - Diabète ...
(Date:7/29/2015)... Asia-Pacific / Japan (Q2 2015: +14% CER ... 2015 on high-single-digit growth in China , as well as ... . Europe / Middle East ... of sales) showed gains in Germany , Turkey ... 2015: +4% CER / 49% of sales) grew 11%, excluding U.S. HPV sales, ...
(Date:7/29/2015)... SAN FRANCISCO , July 29, 2015 /PRNewswire/ ... trialling mobile molecular testing for applications in food ... Ubiquitome,s hand-held, battery powered real-time PCR device, the ... the farm right through to the supermarket shelf ... world. This includes involvement in animal disease control ...
Breaking Biology Technology:Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
... Aug. 31 A high-tech device that expands the visual ... test in a walking simulator, according to scientists at Schepens ... issue of Investigative Ophthalmology and Visual Science. The study ... tiny camera, pocket-sized computer and a transparent computer display on ...
... , , ... or the "Company"), a development-stage company focused on the discovery, ... acute care antibiotic-resistant infections, today announced that one of its ... unique compounds demonstrating efficacy in the treatment of infection in ...
... , , , FREDERICK, Md., Aug. ... Scientist Magazine,s 2009 Top 30 Best Places to Work ... those companies with the most positive work environment, dedicated management, and innovative ... Places to Work Industry award for biotech and pharmaceutical companies. ...
Cached Biology Technology:New Vision Device Passes Virtual Collision Test for People with Tunnel Vision 2New Vision Device Passes Virtual Collision Test for People with Tunnel Vision 3Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria 2Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria 3SABiosciences Ranked 17th on the Best Places to Work Industry Award for Biotech and Pharmaceutical Companies 2
(Date:7/31/2015)... 2015 La 10e Conférence internationale sur ... par le BGI du 22 au 25 octobre ... Chine. La conférence célèbre son 10e ... l,ICG est devenue l,une des réunions annuelles mondiales ... et c,est aussi la plus dynamique, la plus ...
(Date:7/30/2015)... , July 30, 2015 Cellecta, ... for gene function analysis and biomarker discovery, announced ... (sgRNA) Knockout Library targeting all human protein coding ... permanently "knock out" a gene,s function. Cellecta,s new ... high throughput screening tool so that researchers can ...
(Date:7/21/2015)... -- Today, ZTE announced its Android smartphone Axon, featuring ... revenues in 2015 that relate to sales of FPC1025 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... China and we are proud that ... Axon , its first ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... (MGH) researchers have developed a new type of miniature ... expand the application of minimally invasive diagnostic and therapeutic ... the team from the Wellman Center for Photomedicine at ... its use in a mouse model. , ...
... 4 cases of botulism following cosmetic injections to the ... unlicensed preparation that resulted in toxin levels up to ... a report in the November 22/29 issue of JAMA. ... by the toxins of the spore-forming bacterium Clostridium botulinum ...
... collaborating institutions report in this week's Science a ... 2.8 kilometers below Earth's surface. Think that's weird? ... water molecules to useable energy. , The ... the three-dimensional shell that encompasses all planetary life. ...
Cached Biology News:Three-dimensional, miniature endoscope opens new diagnostic possibilities 2Highly concentrated botulinum preparation for cosmetic injections can result in severe illness 2Highly concentrated botulinum preparation for cosmetic injections can result in severe illness 3Bacteria that use radiated water as food 2Bacteria that use radiated water as food 3
...
... Purification Kit is designed for isolating DNA from ... protocol can be completed in less than one ... larger amounts of DNA. The purified DNA can ... Southern blotting. The MasterPure Kit was designed for ...
Caspase Activity Detector, SR-VAD-FMK Kit , 100 tests Consult technical datasheet for details....
HistoScan AP Universal Goat Kit...
Biology Products: